Lexicon Pharmaceuticals Inc (OQ:LXRX)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 8800 TECHNOLOGY FOREST PLACE
8800 TECHNOLOGY FOREST PLACE
THE WOODLANDS TX 77381
Tel: N/A
Website: https://www.lexpharma.com
IR: See website
<
Key People
Jeffrey L. Wade
President, Chief Financial Officer
Lonnel Coats
Chief Executive Officer, Director
Alan J. Main
Executive Vice President - Innovation and Chemical Sciences
Brian T. Crum
Senior Vice President, General Counsel
Thomas Garner
Senior Vice President and Chief Commercial Officer
Craig B. Granowitz
Senior Vice President, Chief Medical Officer
Kenneth B. Kassler-Taub
Senior Vice President - Regulatory and Quality Assurance
Kristen L. Alexander
Vice President - Finance and Accounting
Wendy E. Mcdermott
Vice President - Human Resources
Business Overview
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The Company pipeline includes INPEFA (sotagliflozin), LX9211, and LX9851. Sotagliflozin is an orally delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes mellitus, chronic kidney disease and other cardiovascular risk factors. LX9211 is an orally delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. The Company is conducting preclinical development of LX9851, an orally delivered small molecule drug candidate, as a treatment for obesity and tool for weight management.
Financial Overview
For the fiscal year ended 31 December 2023, Lexicon Pharmaceuticals Inc revenues increased from $139K to $1.2M. Net loss increased 74% to $177.1M. Revenues reflect Net product revenue increase from $0K to $1.1M. Higher net loss reflects Personnel expenses increase from $18.8M to $53M (expense), General and administrative - other increase from $22M to $51.8M (expense), Other Expenses increase from $2.8M to $13.1M (expense).
Employees: 285 as of Mar 21, 2024
Reporting Currency: U.S. Dollars
Enterprise value: $308.69M as of Dec 31, 2023
Annual revenue (TTM): $1.21M as of Dec 31, 2023
EBITDA (TTM): -$171.20M as of Dec 31, 2023
Net annual income (TTM): -$177.12M as of Dec 31, 2023
Free cash flow (TTM): -$162.37M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 246,236,753 as of Mar 21, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.